Table 1

Patient characteristics at diagnosis, overall and by treatment received in patients with incident stage IIIB–IV NSCLC

All
(N=2119)
n (%)
Untreated
(n=1471)
n (%)
SACT treated
(n=648)
n (%)
Age at diagnosis, years
 <65541 (25.5)249 (16.9)292 (45.1)
 65–74671 (31.7)428 (29.1)243 (37.5)
 ≥75907 (42.8)794 (54.0)113 (17.4)
Diagnosis year
 2007–20121181 (55.7)843 (57.3)338 (52.2)
 2013–2017938 (44.3)628 (42.7)310 (47.8)
Sex
 Male1106 (52.2)755 (51.3)351 (54.2)
 Female1013 (47.8)716 (48.7)297 (45.8)
BMI
 <18.5 (underweight)37 (1.7)5 (0.3)32 (4.9)
 18.5–24.9 (healthy weight)299 (14.1)38 (2.6)261 (40.3)
 25–29.9 (overweight)248 (11.7)29 (2.0)219 (33.8)
 ≥30 (obese)118 (5.6)12 (0.8)106 (16.4)
 Missing/unknown1417 (66.9)1387 (94.3)30 (4.6)
ECOG PS
 0145 (6.8)44 (3.0)101 (15.6)
 1517 (24.4)231 (15.7)286 (44.1)
 2414 (19.5)256 (17.4)158 (24.4)
 3564 (26.6)518 (35.2)46 (7.1)
 4284 (13.4)278 (18.9)6 (0.9)
 Missing/unknown195 (9.2)144 (9.8)51 (7.9)
Pathology
 NSQ666 (31.4)366 (24.9)300 (46.3)
 SQ396 (18.7)216 (14.7)180 (27.8)
 Other49 (2.3)20 (1.3)29 (4.5)
 NOS NSCLC315 (14.9)201 (13.7)114 (17.6)
 Clinically diagnosed*693 (32.7)668 (45.4)25 (3.8)
Stage
 IIIB337 (15.9)198 (13.5)139 (21.4)
 IV1782 (84.1)1273 (86.5)509 (78.6)
  • *No pathological confirmation. A total of 25 patients were recorded as receiving treatment following clinical diagnosis; however, further investigations confirmed that all these patients had pathologically confirmed NSCLC.

  • BMI, body mass index; ECOG, Eastern Cooperative Oncology Group; NOS, not otherwise specified; NSCLC, non-small cell lung cancer; NSQ, non-squamous; PS, performance status; ref, reference; SACT, systemic anticancer therapy; SQ, squamous.